INTRODUCTION
It has been known from the start of the HIV epidemic that the central nervous system can be affected by the disease. The presence of neuropathological abnormalities in a majority of cases of advanced HIV disease, even in the absence of a clinical neurological syndrome, has been well documentedl>. Clinical neurological syndromes occur in a majority of cases of HIV6,7. HIV has been found in CSF and neural tissue of subjects at all stages of HIV infection, and these neural products can be used to transfer infection in the laboratoryvU.
In 1986 New York neurologists described a syndrome of dementia associated with HIV infection which they termed'AIDS dementia complex' (ADC) on the grounds that, in addition to occurring in patients with AIDS, it included a range of disturbances such as motor abnormalities, which are not usually part of dementia. Navia et al. 12 claimed that about one third of their patients had ADC when AIDS was diagnosed, and by the terminal stages of illness, ADC was present in as many as two-thirds. Needless to say, the prospect of this new manifestation of AIDS gave raise to a good deal of alarm in people with HIV infection, their carers and relatives, as well as those involved in providing and planning care for HIV disease. Exaggerated but predictable responses ensued, such as calls for putting a stop to the closure of Victorian mental hospitals so as to have facilities for people with demential". Further alarm followed reports in 1987 14 claiming that neuropsychological deficits could be detected in otherwise asymptomatic HIV seropositives. The latter claim led not just to concern, but to calls for the routine testing of aircraft pilots, people taking driving tests and many others. Sadly, such calls are still being made, as in the case of the recent statement by the American Aerospace Medical Association15.
In contrast with these reports, the experience of other clinicians and researchers, many on this side of the Atlantic, has been that HIV-associated dementia is a relatively rare event-s, and that neuropsychological def~cits (not ?mou~ting to dementia) are only seen m people WIth evidence of Correspondence to: Dr J Catalan, Senior Lecturer in Liaison Psychiatry, Charing Cross and Westminster Medical School, 1 Udall Street, London SWIP, UK significant immune deficiency!", Although doubts about the assumptions being made in relation to HIV-associated dementia were voiced earlyI8-20, a second line of argument that has recently been put forward is that the rarity of HIV-associated dementia is a new phenomenon, and one that results from the introduction of anti-retroviral treatment, specifically zidovudine (AZT).
What are we to make of these contradictory claims and counter-claims? Here we shall attempt to clear the undergrowth and examine the evidence, and consider what further steps of inquiry might be worth following.
HIV-ASSOCIATED DEMENTIA THEN AND NOW
Part of the confusion surrounding HIV-associated dementia has to do with how this term is used. Standard textbook and international classification systems define dementia as a syndrome of severe acquired global intellectual deterioration c~aracter ized, in particular by memory dysfunction a~d resulting in impairment in activities of d~dy living-". Grateful as we must be to those :vho~Irst described the syndrome of ADC for having highlighted this clinical disorder--P, it is clear that t~e original description included more than dem~ntIa in the usual sense of the word, and that patI.ents with a variety of neurological and, pOSSIbly, psychiatric disorders were grouped togeth~~under a novel label. In particular, motor abnormahtIes and myelopathies which might or might not have been associated with cognitive impairment were ass~~ed to be part of the ' dementia complex'. The clinical staging used by this group in. subsequent publications 22 ,23 has perp~tuated this~<:>nceptu~l and terminological confusion-", In addition. until recently a proliferation of terms, some based ,on clinical descriptions and others on neuropatholOgIcal images, has hampered progress in our un~e~ standing of HIV-associated dementia. All, this IS reflected in the imprecise manner in whICh the concept of dementia is used by researchers as well as clinicians.
Although much has been made of the fact that the original report found one third of patients wit~early AIDS to be suffering from ADC and two-thIrds by the time they had reached the advanced stages of AIDS, careful reading of the original papers makes clear the reason that these figures may not be altogether reliable. Leaving aside the question of whether the definition is over-inclusive, the study was retrospective and there is no suggestion that the patients were in any way representative of people with AIDS, as they consist of a selected group of individuals referred for a neurological opinion. Interestingly, another study of AIDS patients referred to a neurologist found dementia only in 16% of patients", Early reports based on unselected samples indicate a much lower prevalence. Among those included in the second WHO Consultation Meeting-", prevalence was found to be as low as 8% in one study, and in the study of AIDS cases reported to the Centers for Disease Control in the USA between 1987 and 1988, dementia was found in 6.5% of adults", Two state-of-the-art plenary talks at the VIII International AIDS Conference (1992~in Amsterdam throw some light on the question of the prevalence of HIV-associated dementia. Maj presented some preliminary results from the WHO Multi-centre Study of Neuropsychological Performance in HIV disease, baseline cross-sectional data showing striking similarities in the prevalence of dementia in the 5 centres surveyed (Bangkok, Kinshasa, Munich, Nairobi and Sao Paolo), whether using DSM-I1I or ICD-I0 dementia definitions. Dementia was found in under 7% of AIDS patients, and it was never seen in persons with HIV without other symptoms. MacArthur presented data from the Multicenter AIDS Cohort Study (MACS) showing a yearly incidence of 7% in AIDS, reaching 14% at the 2 year follow-up.
HAS THERE BEEN A CHANGE IN THE PREVALENCE OF HIV-ASSOCIATED DEMENTIA?
As mentioned above, it has been argued in recent years that the syndrome has become less common, and that this is the result of the introduction of zidovudine (AZT). This is an appealing claim, but one difficult to prove. It is not possible to be absolutely certain of the exact prevalence in the early years of the epidemic, as no operationall~defined clinical classifications were in use at the time, and so it is difficult to make adequate comparisons, but what evidence there is that AZT might have contributed to a decline in dementia is far from conclusive.
Schmitt et ai. 27 carried out a double-blind placebo-controlled trial of AZT in patients with ARC and AIDS, and found improved cognitive performance in the experimental group compared with placebo. The follow-up was however only 16 weeks and it is not known whether there would have been any long-term differences. It is also important to stress that no subject had HIV-associated dementia at the outset. Uncontrolled investigations have also suggested that AZT may contribute to improvement in neuropsychological functioning or even to reversal of neurological symptomatology28, 29 . It has been argued that the decline in the diagnosis of ADC30,31 and in the frequency of neuropathological evidence of Hlv-encephalopathy'? parallels the use of zidovudine.
However, these claims are variations on the post hoc, propter hoc theme: when one event follows another, it can not be concluded that the first is the cause of the second. If there has been a change in the prevalence of dementia, other factors apart from the use of AZT need to be considered: the manifestations of the disease may be altering because HIV may have changed; the effects of prolonged survival and combination of treatments could playa part; diagnostic labels may not be used consistently over time; clinicians may be more prone to investigate neuropsychiatric syndromes to exclude secondary complications; and the populations on which the observations are being made may not be comparable.
Results from the recently published randomized study comparing early with late use of zidovudinev showing delayed progression to sympt~matic disease in the early therapy group but Without survival advantage, also showed that there were no cases of dementia in the early therapy group, compared with 6 cases in the late treatment group. Numbers are too small for any meaningful statistics, but the findings are encouraging, and point to the kind of research that is needed to clarify the role of AZT in prevention and treatment of HIV-associated dementia.
MINOR NEUROPSYCHOLOGICAL DEFICITS IN HIV INFECTION
While dementia in advanced HIV-disease seems to be a relatively rare phenomenon, minor neuropsychological deficits are more cornmon. Controlled studies have shown that people with AIDS differ from comparable negative controls regarding test performance, and the domains usually found to differ include visuo-spatial abilities 34,35, nonverbal mernory-"..36, verbal memory36, psychomotor speed34-36, abstract thinking'", and motor control>. Baseline results from the WHO Multi-centre study, as reported by Maj at the VIII International AIDS Conference, suggested that about 20% of symptomatic patients have minor cognitive impairments. Whether there is a relationship between this kind of minor deficit and the subsequent development of dementia is not clear, and to date there is no evidence that it is a predictor of major decline.
To return to symptomatic Hlv patients, the debate about the possible presence of minor neuropsychological deficits in this group seems to be reaching a consensus. While a number of well conducted studies have found differences between groups36-38, the majority of studies, both crosssectional and prospective, have failed to find statistically significant differences between HIV asymptomatics and comparable seronegative controls 39 -46 • As the 1990 WHO consultation meeting report states, 'the weight of current evidence suggests that the great majority of persons in CDC groups II and III do not have impaired performance on neuropsychological tests'25. The implication, supported by the research evidence quoted above, is that a minority of asymptomatics may well have evidence of deficits-what remains unclear is the size of this group and the reasons why deficits appear, and in particular, whether confounding factors unrelated to HIV or methodological problems may be responsible [see Riccio and Burgess''" for detailed discussion] .
SUMMARY AND FURTHER QUESTIONS
In summary, HIV-associated dementia appears to be less common than was once feared and, if it occurs, it tends to do so in the late stages of symptomatic disease. A proportion of people with AIDS, perhaps about one-fifth, have minor neuropsychological deficits short of dementia, but these minor deficits are not seen in asymptomatics.
Several important questions remain. First, the mechanisms involved in central nervous system dysfunction in HIV disease are unclear''. Current interest is focused on the possible role of quinolinic acid 48 and calcium and NMDA receptor-operated channels'", amongst others. Second, the prevention and treatment of central nervous system dysfunction should be a priority. Research needs to be carried out to evaluate the efficacyof anti-retrovirals old and new, as well as new drugs which have in vitro effects on the putative mechanisms of cerebral dysfunction. Finally, the practical, psychosocial care of people with major HIV-related cerebral disease needs to be addressed, using an imaginative combination of community and residential care.
